Medicover Ulm MVZ, Münsterplatz 6, 89073, Ulm, Germany.
School of Medicine, Department of Medicine II, Technical University of Munich, University Hospital Klinikum rechts der Isar, Ismaninger Str. 22, 81675, München, Germany.
Infection. 2020 Oct;48(5):681-686. doi: 10.1007/s15010-020-01438-z. Epub 2020 May 11.
Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population.
Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome.
Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir.
This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.
关于当前 SARS-CoV-2 大流行中人类免疫缺陷病毒(PLWH)感染者的数据仍然很少。本研究纳入了 33 例 COVID-19 感染的 PLWH 患者,揭示了该特殊人群的症状和结局。
对包括年龄、性别、HIV 相关参数、症状和结局在内的匿名数据进行回顾性分析。
32 例有记录结局的患者中死亡 3 例(9%)。91%的患者康复,76%的患者被归类为轻症。所有患者均接受抗逆转录病毒治疗,其中 22 例接受含替诺福韦方案,4 例接受蛋白酶抑制剂达芦那韦。
本初步病例系列研究不支持有症状 COVID-19 PLWH 发病率和死亡率过高,且 ART 病毒抑制良好。SARS-CoV-2 感染可能发生在基于达芦那韦增效和/或含替诺福韦的 ART 期间。